Renalytix PLC Appointment of Joint Corporate Broker
21 August 2024 - 4:00PM
RNS Regulatory News
RNS Number : 1687B
Renalytix PLC
21 August 2024
Renalytix
plc
("Renalytix" or the
"Company")
Appointment of Joint
Corporate Broker
LONDON and NEW YORK, 21 August 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial
intelligence-enabled in vitro diagnostics company, focused on
optimizing clinical management of kidney disease to drive improved
patient outcomes and advance value-based care, announces the appointment of Oberon Capital (a trading name of
Oberon Investments Limited) as Joint Corporate Broker with
immediate effect.
For further information,
please contact:
Renalytix plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via Walbrook
PR
|
|
|
Stifel (Nominated Adviser and Joint Broker)
|
Tel: 020 7710
7600
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
Oberon Capital (Joint Broker)
|
Tel: 020 3179
5300
|
Mike Seabrook / Nick
Lovering
|
|
Investec Bank plc (Joint Broker)
|
Tel: 020 7597
4000
|
Gary Clarence / Shalin
Bhamra
|
|
|
|
Walbrook PR Limited
|
Tel: 020 7933
8780 or renalytix@walbrookpr.com
|
Alice Woodings / Charlotte
Edgar
|
Mob: 07407
804 654 / 07884 664 686
|
|
|
CapComm Partners
|
|
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX)
is an in-vitro diagnostics and laboratory services company that is
the global founder and leader in the new field of bioprognosis™ for
kidney health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPPMMLTMTMTBTI
Renalytix (LSE:RENX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From Oct 2023 to Oct 2024